Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Foghorn Therapeutics Inc (NQ: FHTX ) 5.520 +0.280 (+5.34%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 112,533 Open 5.210 Bid (Size) 5.330 (1) Ask (Size) 5.700 (1) Prev. Close 5.240 Today's Range 5.210 - 5.830 52wk Range 2.700 - 9.970 Shares Outstanding 36,936,886 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June May 28, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline May 22, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Performance YTD -14.42% -14.42% 1 Month -4.83% -4.83% 3 Month -9.06% -9.06% 6 Month -16.87% -16.87% 1 Year -37.13% -37.13% More News Read More Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants May 20, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics: Q4 Earnings Insights March 07, 2024 Via Benzinga FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 06, 2024 Via InvestorPlace Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update May 06, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer April 16, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs April 09, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference April 05, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting March 26, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023 March 07, 2024 Via InvestorPlace Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook March 07, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909 March 05, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference February 28, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session February 08, 2024 Via Benzinga Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher February 08, 2024 Via Benzinga Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor February 08, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024 January 08, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Announces CFO Departure January 03, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting December 01, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update November 02, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs October 24, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress October 13, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference October 04, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences September 05, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
